Carbonic	carbonic	JJ	O
anhydrases	anhydrase	NNS	O
are	be	VBP	O
metalloenzymes	metalloenzymes	NNP	O
widespread	widespread	JJ	O
in	in	IN	O
nature	nature	NN	O
,	,	,	O
being	be	VBG	O
encoded	encode	VBN	O
by	by	IN	O
at	at	RB	O
least	least	RBS	O
eight	eight	CD	O
different	different	JJ	O
genetic	genetic	JJ	O
families	family	NNS	O
,	,	,	O
which	which	WDT	O
have	have	VBP	O
been	be	VBN	O
identified	identify	VBN	O
in	in	IN	O
organisms	organism	NNS	O
all	all	RB	O
over	over	IN	O
the	the	DT	O
phylogenetic	phylogenetic	JJ	O
tree	tree	NN	B
.	.	.	O

By	by	IN	O
catalysing	catalyse	VBG	O
a	a	DT	O
crucial	crucial	JJ	O
physiologic	physiologic	JJ	O
reaction	reaction	NN	O
,	,	,	O
by	by	IN	O
which	which	WDT	O
CO2	CO2	NNP	O
is	be	VBZ	O
hydrated	hydrate	VBN	O
with	with	IN	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
a	a	DT	O
weak	weak	JJ	O
base	base	NN	O
and	and	CC	O
a	a	DT	O
strong	strong	JJ	O
acid	acid	NN	O
,	,	,	O
these	these	DT	O
enzymes	enzyme	NNS	O
are	be	VBP	O
involved	involve	VBN	O
in	in	IN	O
a	a	DT	O
multitude	multitude	NN	O
of	of	IN	O
physiologic	physiologic	JJ	O
processes	process	NNS	O
,	,	,	O
starting	start	VBG	O
with	with	IN	O
pH	pH	NNP	O
regulation	regulation	NN	O
and	and	CC	O
ending	end	VBG	O
with	with	IN	O
metabolism	metabolism	NN	B
,	,	,	B
.	.	.	O

As	as	IN	O
thus	thus	RB	O
,	,	,	O
CAs	ca	NNS	O
are	be	VBP	O
drug	drug	NN	O
targets	target	NNS	O
for	for	IN	O
decades	decade	NNS	O
,	,	,	O
with	with	IN	O
their	-PRON-	PRP$	O
inhibitors	inhibitor	NNS	O
having	have	VBG	O
pharmacological	pharmacological	JJ	O
applications	application	NNS	O
in	in	IN	O
a	a	DT	O
multitude	multitude	NN	O
of	of	IN	O
fields	field	NNS	B
,	,	,	B
.	.	.	O

The	the	DT	O
primary	primary	JJ	O
sulphonamides	sulphonamide	NNS	O
were	be	VBD	O
discovered	discover	VBN	O
as	as	IN	O
CA	CA	NNP	O
inhibitors	inhibitor	NNS	O
in	in	IN	O
the	the	DT	O
40âs	40âs	CD	O
,	,	,	O
and	and	CC	O
most	most	JJS	O
of	of	IN	O
the	the	DT	O
drugs	drug	NNS	O
that	that	WDT	O
were	be	VBD	O
launched	launch	VBN	O
in	in	IN	O
the	the	DT	O
next	next	JJ	O
decades	decade	NNS	O
as	as	IN	O
diuretics	diuretic	NNS	O
,	,	,	O
antiepileptics	antiepileptic	NNS	O
,	,	,	O
or	or	CC	O
antiglaucoma	antiglaucoma	NNP	O
agents	agent	NNS	O
targeting	target	VBG	O
CAs	CAs	NNP	O
belonged	belong	VBD	O
to	to	IN	O
this	this	DT	O
class	class	NN	O
of	of	IN	O
compounds	compound	NNS	B
,	,	,	B
.	.	.	O

Although	although	IN	O
highly	highly	RB	O
effective	effective	JJ	O
as	as	IN	O
CAIs	CAIs	NNP	B
,	,	,	O
the	the	DT	O
sulphonamides	sulphonamide	NNS	O
generally	generally	RB	O
indiscriminately	indiscriminately	RB	O
inhibit	inhibit	VBP	O
most	most	JJS	O
Î±-CA	î±-ca	JJ	O
isoforms	isoform	NNS	O
present	present	JJ	O
in	in	IN	O
mammals	mammal	NNS	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
CAs	ca	NNS	O
belonging	belong	VBG	O
to	to	IN	O
the	the	DT	O
other	other	JJ	O
genetic	genetic	JJ	O
families	family	NNS	O
Î²-	î²-	UH	O
,	,	,	O
Î³-	î³-	UH	O
,	,	,	O
Î´-	Î´-	NNP	O
,	,	,	O
Î¶-	î¶-	CD	O
,	,	,	O
Î·-	Î·-	NNP	O
,	,	,	O
Î¸-	Î¸-	NNP	O
and	and	CC	O
Î¹-CAs	Î¹-CAs	NNP	O
)	)	-RRB-	B
and	and	CC	O
for	for	IN	O
this	this	DT	O
reason	reason	NN	O
alternative	alternative	JJ	O
CAI	CAI	NNP	O
classes	class	NNS	O
were	be	VBD	O
searched	search	VBN	O
for	for	IN	O
.	.	.	O

In	in	IN	O
fact	fact	NN	O
,	,	,	O
in	in	IN	O
the	the	DT	O
last	last	JJ	O
10âyears	10âyears	CD	O
,	,	,	O
a	a	DT	O
multitude	multitude	NN	O
of	of	IN	O
new	new	JJ	O
chemotypes	chemotype	NNS	O
as	as	RB	O
well	well	RB	O
as	as	IN	O
novel	novel	NN	O
CA	CA	NNP	O
inhibition	inhibition	NN	O
mechanisms	mechanism	NNS	O
were	be	VBD	O
reported	report	VBN	B
,	,	,	B
,	,	,	B
,	,	,	O
which	which	WDT	O
highly	highly	RB	O
enriched	enrich	VBD	O
our	-PRON-	PRP$	O
understanding	understanding	NN	O
of	of	IN	O
these	these	DT	O
enzymes	enzyme	NNS	O
and	and	CC	O
also	also	RB	O
allowed	allow	VBN	O
for	for	IN	O
obtaining	obtain	VBG	O
isoform	isoform	NN	O
-	-	HYPH	O
selective	selective	NN	O
CAIs	cai	NNS	O
targeting	target	VBG	O
all	all	PDT	O
the	the	DT	O
mammalian	mammalian	JJ	O
isoforms	isoform	NNS	B
,	,	,	B
.	.	.	O

Among	among	IN	O
the	the	DT	O
new	new	JJ	O
such	such	JJ	O
chemotypes	chemotype	NNS	O
,	,	,	O
which	which	WDT	O
also	also	RB	O
showed	show	VBD	O
the	the	DT	O
highest	high	JJS	O
levels	level	NNS	O
of	of	IN	O
isoform	isoform	JJ	O
selectivity	selectivity	NN	O
,	,	,	O
were	be	VBD	O
the	the	DT	O
coumarins	coumarin	NNS	B
,	,	,	O
the	the	DT	O
sulfocoumarins	sulfocoumarin	NNS	B
,	,	,	B
and	and	CC	O
their	-PRON-	PRP$	O
congeners	congener	NNS	O
,	,	,	O
homosulfocoumarins	homosulfocoumarin	VBZ	B
.	.	.	O

Considering	consider	VBG	O
the	the	DT	O
fact	fact	NN	O
that	that	IN	O
this	this	DT	O
last	last	JJ	O
chemotype	chemotype	NN	O
was	be	VBD	O
only	only	RB	O
recently	recently	RB	O
reported	report	VBN	O
and	and	CC	O
rather	rather	RB	O
poorly	poorly	RB	O
investigated	investigate	VBN	B
,	,	,	O
we	-PRON-	PRP	O
report	report	VBP	O
here	here	RB	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
new	new	JJ	O
aryl-3H-1,2-benzoxathiepine	aryl-3H-1,2-benzoxathiepine	NNP	O
2,2-dioxides	2,2-dioxides	CD	O
substituted	substitute	VBN	O
in	in	IN	O
various	various	JJ	O
positions	position	NNS	O
of	of	IN	O
the	the	DT	O
heterocyclic	heterocyclic	JJ	O
ring	ring	NN	O
,	,	,	O
which	which	WDT	O
have	have	VBP	O
been	be	VBN	O
designed	design	VBN	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
explore	explore	VB	O
the	the	DT	O
chemical	chemical	NN	O
space	space	NN	O
around	around	IN	O
this	this	DT	O
new	new	JJ	O
CA	CA	NNP	O
inhibitory	inhibitory	NN	O
chemotype	chemotype	NN	O
and	and	CC	O
to	to	TO	O
see	see	VB	O
whether	whether	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
various	various	JJ	O
moieties	moiety	NNS	O
in	in	IN	O
position	position	NN	O
7	7	CD	O
,	,	,	O
8	8	CD	O
or	or	CC	O
9	9	CD	O
of	of	IN	O
the	the	DT	O
heterocyclic	heterocyclic	JJ	O
system	system	NN	O
maintains	maintain	VBZ	O
the	the	DT	O
desired	desire	VBN	O
enzyme	enzyme	NNS	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
and	and	CC	O
selectivity	selectivity	NN	O
for	for	IN	O
the	the	DT	O
target	target	NN	O
isoforms	isoform	NNS	O
.	.	.	O

Reagents	reagent	NNS	O
,	,	,	O
starting	start	VBG	O
materials	material	NNS	O
and	and	CC	O
solvents	solvent	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
commercial	commercial	JJ	O
sources	source	NNS	O
and	and	CC	O
used	use	VBN	O
as	as	IN	O
received	receive	VBN	O
.	.	.	O

Thin	thin	JJ	O
-	-	HYPH	O
layer	layer	NN	O
chromatography	chromatography	NN	O
was	be	VBD	O
performed	perform	VBN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
,	,	,	O
spots	spot	NNS	O
were	be	VBD	O
visualised	visualise	VBN	O
with	with	IN	O
UV	UV	NNP	O
light	light	NN	O
254	254	CD	O
and	and	CC	O
365ânm	365ânm	CD	O
.	.	.	O

Melting	melt	VBG	O
points	point	NNS	O
were	be	VBD	O
determined	determine	VBN	O
on	on	IN	O
an	an	DT	O
OptiMelt	OptiMelt	NNP	O
automated	automate	VBN	O
melting	melting	NN	O
point	point	NN	O
system	system	NN	O
.	.	.	O

IR	IR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
Shimadzu	Shimadzu	NNP	O
FTIR	FTIR	NNP	O
IR	IR	NNP	O
Prestige-21	Prestige-21	NNS	O
spectrometer	spectrometer	VBP	O
.	.	.	O

NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
Bruker	Bruker	NNP	O
Advance	Advance	NNP	O
Neo	Neo	NNP	O
400âMHz	400âmhz	CD	O
spectrometer	spectrometer	VB	O
with	with	IN	O
chemical	chemical	NN	O
shifts	shift	NNS	O
values	value	NNS	O
Î	Î	NNP	O
´	´	NNP	O
in	in	IN	O
ppm	ppm	NNP	O
relative	relative	JJ	O
to	to	IN	O
TMS	TMS	NNP	O
using	use	VBG	O
the	the	DT	O
residual	residual	JJ	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NNP	O
signal	signal	NN	O
1H	1H	NNP	O
2.50	2.50	CD	O
;	;	:	O
13âC	13âc	CD	O
39.52	39.52	CD	O
or	or	CC	O
CDCl3	CDCl3	NNP	O
signal	signal	NNP	O
1H	1H	NNP	O
7.26	7.26	CD	O
;	;	:	O
13âC	13âc	CD	O
77.16	77.16	CD	O
as	as	IN	O
an	an	DT	O
internal	internal	JJ	O
standard	standard	NN	O
.	.	.	O

High	high	JJ	O
-	-	HYPH	O
resolution	resolution	NN	O
mass	mass	NN	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
a	a	DT	O
mass	mass	NN	O
spectrometer	spectrometer	NN	O
with	with	IN	O
a	a	DT	O
Q	Q	NNP	O
-	-	HYPH	O
TOF	TOF	NNP	O
micro	micro	NNP	O
mass	mass	NNP	O
analyser	analyser	NNP	O
using	use	VBG	O
the	the	DT	O
ESI	ESI	NNP	O
technique	technique	NN	O
.	.	.	O

Elemental	elemental	JJ	O
analyses	analysis	NNS	O
were	be	VBD	O
measured	measure	VBN	O
using	use	VBG	O
Carlo	Carlo	NNP	O
Erba	Erba	NNP	O
apparatus	apparatus	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
salicylaldehyde	salicylaldehyde	NN	O
8.73âmL	8.73âml	CD	O
,	,	,	O
81.9âmmol	81.9âmmol	NNP	O
in	in	IN	O
AcOH	acoh	NN	O
40âmL	40âml	LS	O
iodine	iodine	NN	O
monochloride	monochloride	NN	O
4.92âmL	4.92âml	CD	O
,	,	,	O
98.3âmmol	98.3âmmol	NNP	O
was	be	VBD	O
added	add	VBN	B
.	.	.	O

Reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
24âh	24âh	CD	O
at	at	IN	O
40âÂ	40ââ	CD	O
°	°	NNPS	O
C	C	NNP	O
,	,	,	O
then	then	RB	O
cooled	cool	VBD	O
to	to	IN	O
r.t	r.t	NNP	O
.	.	NNP	O

EtOH	EtOH	NNP	O
60âmL	60âml	CD	O
was	be	VBD	O
added	add	VBN	O
and	and	CC	O
all	all	DT	O
volatiles	volatile	NNS	O
were	be	VBD	O
removed	remove	VBN	O
in	in	IN	O
vacuum	vacuum	NN	O
.	.	.	O

CH2Cl2	ch2cl2	NN	O
60âmL	60âml	CD	O
and	and	CC	O
water	water	NN	O
100âmL	100âml	CD	O
were	be	VBD	O
added	add	VBN	O
,	,	,	O
the	the	DT	O
phases	phase	NNS	O
were	be	VBD	O
separated	separate	VBN	O
and	and	CC	O
the	the	DT	O
aqueous	aqueous	JJ	O
phase	phase	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
CH2Cl2	CH2Cl2	NNP	O
3âÃâ50âmL	3âãâ50âml	NN	O
.	.	.	O

The	the	DT	O
combined	combined	JJ	O
organic	organic	JJ	O
phases	phase	NNS	O
were	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
10	10	CD	O
%	%	NN	O
Na2S2O3	na2s2o3	NN	O
1âÃâ60âmL	1âãâ60âml	NN	O
,	,	,	O
brine	brine	NN	O
1âÃâ60âmL	1âãâ60âml	NN	O
,	,	,	O
dried	dry	VBN	O
over	over	IN	O
Na2SO4	Na2SO4	NNP	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
concentrated	concentrate	VBD	O
.	.	.	O

The	the	DT	O
residue	residue	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
,	,	,	O
the	the	DT	O
crude	crude	JJ	O
product	product	NN	O
was	be	VBD	O
re	re	VBN	O
-	-	VBN	O
crystallised	crystallise	VBN	O
from	from	IN	O
EtOH	EtOH	NNP	O
to	to	TO	O
afford	afford	VB	O
product	product	NN	O
2	2	CD	O
17.1âg	17.1âg	CD	O
,	,	,	O
84	84	CD	O
%	%	NN	O
as	as	IN	O
yellowish	yellowish	JJ	O
solid	solid	JJ	O
.	.	.	O

1H	1H	NNP	O
NMR	NMR	NNP	O
400âMHz	400âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î´â=â6.85	Î´â=â6.85	.	O
d	d	NN	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
Jâ=â8.6âHz	Jâ=â8.6âHz	NNP	O
,	,	,	O
7.77	7.77	CD	O
dd	dd	NNP	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
Jâ=â8.6	jâ=â8.6	RB	O
,	,	,	O
2.4âHz	2.4âhz	CD	O
,	,	,	O
7.87	7.87	CD	O
d	d	NN	O
,	,	,	O
1H	1H	NNP	O
,	,	,	O
Jâ=â2.4âHz	jâ=â2.4âhz	NN	O
,	,	,	O
10.16	10.16	CD	O
,	,	,	O
10.92	10.92	CD	O
ppm	ppm	NN	O
.	.	NNP	O

13âC	13âC	NNP	O
NMR	NMR	NNP	O
100âMHz	100âmhz	CD	O
,	,	,	O
DMSO	DMSO	NNP	O
-	-	HYPH	O
d6	d6	NN	O
Î´â=â81.4	î´â=â81.4	NN	O
,	,	,	O
120.1	120.1	CD	O
,	,	,	O
124.6	124.6	CD	O
,	,	,	O
136.7	136.7	CD	O
,	,	,	O
144.1	144.1	CD	O
,	,	,	O
160.3	160.3	CD	O
,	,	,	O
189.8âppm	189.8âppm	CD	O
.	.	.	O

Compound	Compound	NNP	O
was	be	VBD	O
synthesised	synthesise	VBN	O
using	use	VBG	O
previously	previously	RB	O
described	describe	VBN	O
procedure	procedure	NN	O
by	by	IN	O
our	-PRON-	PRP$	O
group	group	NN	B
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
Na2SO3	Na2SO3	NNP	O
30.2âg	30.2âg	CD	O
;	;	:	O
0.24âmol	0.24âmol	NNP	O
in	in	IN	O
water	water	NN	O
140âmL	140âml	CD	O
ally	ally	NN	O
bromide	bromide	NN	O
17.4âmL	17.4âml	CD	O
;	;	:	O
0.20âmol	0.20âmol	NNP	O
was	be	VBD	O
added	add	VBN	O
and	and	CC	O
the	the	DT	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
refluxed	refluxe	VBN	O
overnight	overnight	RB	O
.	.	.	O

After	after	IN	O
cooling	cool	VBG	O
to	to	IN	O
room	room	NN	O
temperature	temperature	NN	O
,	,	,	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
Et2O	Et2O	NNP	O
3âÃâ50âmL	3âãâ50âml	NN	O
.	.	.	O

Aqueous	aqueous	JJ	O
phase	phase	NN	O
was	be	VBD	O
concentrated	concentrated	JJ	O
.	.	.	O

Crude	crude	JJ	O
white	white	JJ	O
solid	solid	JJ	O
was	be	VBD	O
dried	dry	VBN	O
under	under	IN	O
high	high	JJ	O
vacuum	vacuum	NN	O
at	at	IN	O
100âÂ	100ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
6âh	6âh	CD	O
.	.	.	O

To	to	IN	O
the	the	DT	O
white	white	JJ	O
solid	solid	JJ	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	NNP	O
C	C	NNP	O
POCl3	pocl3	NN	O
120âmL	120âml	CD	O
was	be	VBD	O
added	add	VBN	O
,	,	,	O
and	and	CC	O
mixture	mixture	NN	O
was	be	VBD	O
refluxed	refluxe	VBN	O
for	for	IN	O
4âh	4âh	CD	O
.	.	.	O

After	after	IN	O
cooling	cool	VBG	O
to	to	TO	O
room	room	NN	O
temperature	temperature	NN	O
dry	dry	JJ	O
THF	THF	NNP	O
60âmL	60âml	CD	O
was	be	VBD	O
added	add	VBN	O
and	and	CC	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
vigorously	vigorously	RB	O
stirred	stir	VBN	O
for	for	IN	O
10âmin	10âmin	NN	O
and	and	CC	O
filtered	filter	VBN	O
.	.	.	O

Filter	filter	NN	O
cake	cake	NN	O
was	be	VBD	O
suspended	suspend	VBN	O
in	in	IN	O
dry	dry	JJ	O
THF	THF	NNP	O
60âmL	60âml	CD	O
,	,	,	O
suspension	suspension	NN	O
was	be	VBD	O
vigorously	vigorously	RB	O
stirred	stir	VBN	O
for	for	IN	O
10âmin	10âmin	NN	O
and	and	CC	O
filtered	filter	VBN	O
.	.	.	O

Filtrates	filtrate	NNS	O
were	be	VBD	O
combined	combine	VBN	O
and	and	CC	O
solvent	solvent	NN	O
was	be	VBD	O
carefully	carefully	RB	O
driven	drive	VBN	O
off	off	RP	O
on	on	IN	O
rotary	rotary	JJ	O
evaporator	evaporator	NN	O
.	.	.	O

Residue	Residue	NNP	O
was	be	VBD	O
distilled	distil	VBN	O
in	in	IN	O
vacuum	vacuum	NN	O
and	and	CC	O
fraction	fraction	NN	O
with	with	IN	O
boiling	boiling	NN	O
point	point	NN	O
38â42âÂ	38â42âÂ	NNS	O
°	°	,	O
C	C	NNP	O
was	be	VBD	O
collected	collect	VBN	O
,	,	,	O
to	to	TO	O
give	give	VB	O
prop-2-ene-1-sulfonil	prop-2-ene-1-sulfonil	NNP	O
chloride	chloride	NN	O
as	as	IN	O
colourless	colourless	JJ	O
oil	oil	NN	O
18.6âg	18.6âg	CD	O
,	,	,	O
66	66	CD	O
%	%	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
used	use	VBN	O
in	in	IN	O
further	further	JJ	O
reactions	reaction	NNS	O
without	without	IN	O
additional	additional	JJ	O
purification	purification	NN	O
.	.	.	O

To	to	IN	O
a	a	DT	O
stirred	stir	VBN	O
solution	solution	NN	O
of	of	IN	O
methyltriphenylphosphonium	methyltriphenylphosphonium	NN	O
bromide	bromide	NN	O
in	in	IN	O
dry	dry	JJ	O
THF	THF	NNP	O
5âmL/1âmmol	5âml/1âmmol	CD	O
of	of	IN	O
methyltriphenylphosphonium	methyltriphenylphosphonium	NN	O
bromide	bromide	NN	O
,	,	,	O
was	be	VBD	O
added	add	VBN	O
tBuOK	tBuOK	NNP	O
in	in	IN	O
several	several	JJ	O
portions	portion	NNS	O
over	over	IN	O
20âmin	20âmin	NN	O
.	.	.	O

Reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
for	for	IN	O
1âh	1âh	CD	O
at	at	IN	O
r.t	r.t	NNP	O
.	.	.	O

Corresponding	corresponding	JJ	O
benzaldehyde	benzaldehyde	NN	O
was	be	VBD	O
added	add	VBN	O
and	and	CC	O
stirring	stir	VBG	O
continued	continue	VBN	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
for	for	IN	O
24âh	24âh	CD	O
.	.	.	O

Reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
diluted	dilute	VBN	O
with	with	IN	O
CH2Cl2	CH2Cl2	NNP	O
4âmL/1âmmol	4âml/1âmmol	CD	O
of	of	IN	O
methyltriphenylphosphonium	methyltriphenylphosphonium	NN	O
bromide	bromide	NN	O
.	.	.	O

Organic	organic	JJ	O
layer	layer	NN	O
was	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
water	water	NN	O
2âÃâ20âmL	2âãâ20âml	LS	O
and	and	CC	O
brine	brine	NNP	O
2âÃâ20âmL	2âÃâ20âmL	NNP	O
,	,	,	O
and	and	CC	O
dried	dry	VBN	O
over	over	IN	O
Na2SO4	Na2SO4	NNP	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
concentrated	concentrate	VBD	O
.	.	.	O

The	the	DT	O
crude	crude	JJ	O
product	product	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
.	.	.	O

Compound	Compound	NNP	O
27	27	CD	O
was	be	VBD	O
prepared	prepare	VBN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
general	general	JJ	O
procedure	procedure	NN	O
from	from	IN	O
methyltriphenylphosphonium	methyltriphenylphosphonium	NN	O
bromide	bromide	NN	O
18.48âg	18.48âg	CD	O
;	;	:	O
51.7âmmol	51.7âmmol	NNP	O
,	,	,	O
t	t	NNP	O
-	-	HYPH	O
BuOK	BuOK	NNP	O
7.15âg	7.15âg	CD	O
;	;	:	O
63.7âmmol	63.7âmmol	NNP	O
and	and	CC	O
3-bromo-2-hydroxybenzaldehyde	3-bromo-2-hydroxybenzaldehyde	CD	O
4.00âg	4.00âg	CD	O
,	,	,	O
19.9âmmol	19.9âmmol	NNP	O
as	as	IN	O
yellowish	yellowish	JJ	O
solid	solid	JJ	O
3.17âg	3.17âg	CD	O
;	;	:	O
80	80	CD	O
%	%	NN	O
)	)	-RRB-	B
.	.	.	O

To	to	IN	O
a	a	DT	O
stirred	stir	VBN	O
solution	solution	NN	O
of	of	IN	O
corresponding	correspond	VBG	O
ethenylphenol	ethenylphenol	NN	O
in	in	IN	O
CH2Cl2	CH2Cl2	NNP	O
10âmL/1âmmol	10âml/1âmmol	CD	O
corresponding	correspond	VBG	O
ethenylphenol	ethenylphenol	NN	O
at	at	IN	O
0âÂ	0ââ	CD	O
°	°	NNP	O
C	C	NNP	O
was	be	VBD	O
added	add	VBN	O
prop-2-ene-1-sulphonyl	prop-2-ene-1-sulphonyl	NN	O
chloride	chloride	NN	O
and	and	CC	O
Et3N	et3n	NN	O
.	.	.	O

Reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
stirred	stir	VBN	O
overnight	overnight	RB	O
20âh	20âh	CD	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
.	.	.	O

Water	water	NN	O
30âmL	30âml	CD	O
was	be	VBD	O
added	add	VBN	O
,	,	,	O
reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
extracted	extract	VBN	O
with	with	IN	O
EtOAc	EtOAc	NNS	O
3âÃâ40âmL	3âãâ40âml	NN	O
,	,	,	O
combined	combine	VBN	O
organic	organic	JJ	O
extracts	extract	NNS	O
were	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
brine	brine	NN	O
2âÃâ40âmL	2âÃâ40âmL	NNP	O
,	,	,	O
and	and	CC	O
dried	dry	VBN	O
over	over	RB	O
dried	dry	VBN	O
over	over	IN	O
Na2SO4	Na2SO4	NNP	O
,	,	,	O
filtered	filter	VBN	O
and	and	CC	O
concentrated	concentrate	VBD	O
.	.	.	O

The	the	DT	O
crude	crude	JJ	O
product	product	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
.	.	.	O

To	to	IN	O
a	a	DT	O
solution	solution	NN	O
of	of	IN	O
corresponding	correspond	VBG	O
diolefine	diolefine	NN	O
in	in	IN	O
dry	dry	JJ	O
,	,	,	O
degassed	degassed	JJ	O
toluene	toluene	JJ	O
15âmL/1âmmol	15âml/1âmmol	CD	O
corresponding	corresponding	JJ	O
diolefine	diolefine	NN	O
ruthenium	ruthenium	NN	O
catalyst	catalyst	NN	O
6	6	CD	O
5âmol	5âmol	CD	O
%	%	NN	O
was	be	VBD	O
added	add	VBN	O
.	.	.	O

Reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
bubbled	bubble	VBN	O
with	with	IN	O
argon	argon	NNP	O
for	for	IN	O
5âmin	5âmin	CD	O
and	and	CC	O
sealed	seal	VBN	O
,	,	,	O
stirred	stir	VBN	O
at	at	IN	O
70âÂ	70âÂ	NNP	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
4âh	4âh	CD	O
.	.	.	O

After	after	IN	O
cooling	cool	VBG	O
to	to	IN	O
r.t	r.t	NNP	O
.	.	.	O

it	-PRON-	PRP	O
was	be	VBD	O
concentrated	concentrate	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
crude	crude	JJ	O
product	product	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NN	O
.	.	.	O

Products	product	NNS	O
were	be	VBD	O
re	re	VBN	O
-	-	VBN	O
crystallised	crystallise	VBN	O
from	from	IN	O
EtOH	EtOH	NNP	O
.	.	.	O

In	in	IN	O
a	a	DT	O
pressure	pressure	NN	O
tube	tube	NN	O
corresponding	correspond	VBG	O
3H-1,2-benzoxathiepine	3h-1,2-benzoxathiepine	CD	O
2,2-dioxide	2,2-dioxide	CD	O
halogen	halogen	NN	O
derivative	derivative	JJ	O
was	be	VBD	O
dissolved	dissolve	VBN	O
in	in	IN	O
dry	dry	JJ	O
toluene	toluene	NN	O
6âmL/1âmmol	6âml/1âmmol	DT	O
corresponding	correspond	VBG	O
3H-1,2-benzoxathiepine	3h-1,2-benzoxathiepine	CD	O
2,2-dioxide	2,2-dioxide	CD	O
halogen	halogen	NN	O
derivative	derivative	JJ	O
,	,	,	O
degassed	degassed	JJ	O
water	water	NN	O
was	be	VBD	O
added	add	VBN	O
,	,	,	O
corresponding	correspond	VBG	O
boronic	boronic	JJ	O
acid	acid	NN	O
,	,	,	O
K3PO4	K3PO4	NNP	O
and	and	CC	O
Pd4	Pd4	NNP	O
.	.	.	O

Reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
bubbled	bubble	VBN	O
with	with	IN	O
argon	argon	NNP	O
5âmin	5âmin	NNP	O
,	,	,	O
tube	tube	NNP	O
was	be	VBD	O
sealed	seal	VBN	O
and	and	CC	O
heated	heat	VBN	O
for	for	IN	O
16âh	16âh	CD	O
at	at	IN	O
100âÂ	100ââ	CD	O
°	°	,	O
C	c	NN	O
temperature	temperature	NN	O
.	.	.	O

Reaction	reaction	NN	O
mixture	mixture	NN	O
was	be	VBD	O
cooled	cool	VBN	O
to	to	IN	O
r.t	r.t	NNP	O
.	.	NNP	O

,	,	,	O
filtered	filter	VBN	O
through	through	IN	O
cellite	cellite	NN	O
was	be	VBD	O
washed	wash	VBN	O
with	with	IN	O
EtOAc	EtOAc	NNS	O
40âmL	40âml	LS	O
.	.	.	O

Mixture	mixture	NN	O
was	be	VBD	O
evaporated	evaporate	VBN	O
and	and	CC	O
crude	crude	JJ	O
product	product	NN	O
was	be	VBD	O
purified	purify	VBN	O
by	by	IN	O
column	column	NN	O
chromatography	chromatography	NN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NN	O
.	.	.	O

Products	product	NNS	O
were	be	VBD	O
re	re	VBN	O
-	-	VBN	O
crystallised	crystallise	VBN	O
from	from	IN	O
EtOH	EtOH	NNP	O
.	.	.	O

An	an	DT	O
Applied	Applied	NNP	O
Photophysics	Photophysics	NNPS	O
stopped	stop	VBD	O
-	-	HYPH	O
flow	flow	NN	O
instrument	instrument	NN	O
has	have	VBZ	O
been	be	VBN	O
used	use	VBN	O
for	for	IN	O
assaying	assay	VBG	O
the	the	DT	O
CA	CA	NNP	O
catalysed	catalyse	VBD	O
CO2	CO2	NNP	O
hydration	hydration	NN	O
activity	activity	NN	B
.	.	.	O

Phenol	Phenol	NNP	O
red	red	JJ	O
at	at	IN	O
a	a	DT	O
concentration	concentration	NN	O
of	of	IN	O
0.2âmM	0.2âmm	NN	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
indicator	indicator	NN	O
,	,	,	O
working	work	VBG	O
at	at	IN	O
the	the	DT	O
absorbance	absorbance	NN	O
maximum	maximum	NN	O
of	of	IN	O
557ânm	557ânm	CD	O
,	,	,	O
with	with	IN	O
20âmM	20âmm	CD	O
Hepes	Hepes	NNPS	O
as	as	IN	O
buffer	buffer	NN	O
and	and	CC	O
20âmM	20âmm	CD	O
Na2SO4	Na2SO4	NNP	O
,	,	,	O
following	follow	VBG	O
the	the	DT	O
initial	initial	JJ	O
rates	rate	NNS	O
of	of	IN	O
the	the	DT	O
CA	CA	NNP	O
-	-	HYPH	O
catalysed	catalyse	VBN	O
CO2	CO2	NNP	O
hydration	hydration	NN	O
reaction	reaction	NN	O
for	for	IN	O
a	a	DT	O
period	period	NN	O
of	of	IN	O
10âââ100âs	10âââ100âs	NNP	O
.	.	.	O

The	the	DT	O
CO2	CO2	NNP	O
concentrations	concentration	NNS	O
ranged	range	VBD	O
from	from	IN	O
1.7	1.7	CD	O
to	to	TO	O
17âmM	17âmm	CD	O
for	for	IN	O
the	the	DT	O
determination	determination	NN	O
of	of	IN	O
the	the	DT	O
kinetic	kinetic	JJ	O
parameters	parameter	NNS	O
and	and	CC	O
inhibition	inhibition	NN	O
constants	constant	NNS	O
.	.	.	O

For	for	IN	O
each	each	DT	O
inhibitor	inhibitor	NN	O
,	,	,	O
at	at	IN	O
least	least	JJS	O
six	six	CD	O
traces	trace	NNS	O
of	of	IN	O
the	the	DT	O
initial	initial	JJ	O
5âââ10	5âââ10	CD	O
%	%	NN	O
of	of	IN	O
the	the	DT	O
reaction	reaction	NN	O
have	have	VBP	O
been	be	VBN	O
used	use	VBN	O
for	for	IN	O
determining	determine	VBG	O
the	the	DT	O
initial	initial	JJ	O
velocity	velocity	NN	O
.	.	.	O

The	the	DT	O
uncatalysed	uncatalysed	JJ	O
rates	rate	NNS	O
were	be	VBD	O
determined	determine	VBN	O
in	in	IN	O
the	the	DT	O
same	same	JJ	O
manner	manner	NN	O
and	and	CC	O
subtracted	subtract	VBD	O
from	from	IN	O
the	the	DT	O
total	total	JJ	O
observed	observed	JJ	O
rates	rate	NNS	O
.	.	.	O

Stock	stock	NN	O
solutions	solution	NNS	O
of	of	IN	O
inhibitor	inhibitor	NN	O
0.1âmM	0.1âmm	CD	O
were	be	VBD	O
prepared	prepare	VBN	O
in	in	IN	O
distilledâââdeionised	distilledâââdeionised	DT	O
water	water	NN	O
,	,	,	O
and	and	CC	O
dilutions	dilution	NNS	O
up	up	RB	O
to	to	IN	O
0.01ânM	0.01ânm	NN	O
were	be	VBD	O
done	do	VBN	O
thereafter	thereafter	RB	O
with	with	IN	O
the	the	DT	O
assay	assay	NN	O
buffer	buffer	NN	O
.	.	.	O

Inhibitor	inhibitor	NN	O
and	and	CC	O
enzyme	enzyme	NNS	O
solutions	solution	NNS	O
were	be	VBD	O
preincubated	preincubate	VBN	O
together	together	RB	O
for	for	IN	O
6âh	6âh	CD	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
prior	prior	RB	O
to	to	IN	O
assay	assay	NNP	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
allow	allow	VB	O
for	for	IN	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
the	the	DT	O
EâââI	EâââI	NNP	O
complex	complex	NN	O
.	.	.	O

The	the	DT	O
inhibition	inhibition	NN	O
constants	constant	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
nonlinear	nonlinear	JJ	O
least	least	JJS	O
-	-	HYPH	O
squares	square	NNS	O
methods	method	NNS	O
using	use	VBG	O
PRISM	PRISM	NNP	O
3	3	CD	O
and	and	CC	O
the	the	DT	O
ChengâââPrusoff	chengâââprusoff	JJ	O
equation	equation	NN	O
,	,	,	O
as	as	IN	O
reported	report	VBN	O
earlier	early	JJR	B
,	,	,	O
and	and	CC	O
represent	represent	VB	O
the	the	DT	O
mean	mean	NN	O
from	from	IN	O
at	at	RB	O
least	least	RBS	O
three	three	CD	O
different	different	JJ	O
determinations	determination	NNS	O
.	.	.	O

All	all	DT	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
were	be	VBD	O
recombinant	recombinant	JJ	O
ones	one	NNS	O
obtained	obtain	VBN	O
in	in	IN	O
-	-	HYPH	O
house	house	NN	O
as	as	IN	O
reported	report	VBN	O
earlier	early	JJR	B
,	,	,	B
.	.	.	O

The	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
desired	desire	VBN	O
compounds	compound	NNS	O
is	be	VBZ	O
partly	partly	RB	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
strategy	strategy	NN	O
previously	previously	RB	O
developed	develop	VBN	O
by	by	IN	O
our	-PRON-	PRP$	O
groups	group	NNS	B
.	.	.	O

The	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
7-aryl	7-aryl	CD	O
3H-1,2-benzoxathiepine	3h-1,2-benzoxathiepine	CD	O
2,2-dioxides	2,2-dioxides	CD	O
starts	start	VBZ	O
with	with	IN	O
the	the	DT	O
iodination	iodination	NN	O
of	of	IN	O
salicylaldehyde	salicylaldehyde	NNP	O
by	by	IN	O
iodine	iodine	NN	O
monochloride	monochloride	NN	O
and	and	CC	O
corresponding	correspond	VBG	O
iodo	iodo	JJ	O
derivative	derivative	JJ	O
2	2	CD	O
was	be	VBD	O
isolated	isolate	VBN	O
in	in	IN	O
good	good	JJ	O
yield	yield	NN	B
.	.	.	O

Under	under	IN	O
Wittig	wittig	NN	O
reaction	reaction	NN	O
conditions	condition	NNS	O
aldehyde	aldehyde	JJ	O
2	2	CD	O
was	be	VBD	O
converted	convert	VBN	O
to	to	TO	O
olefin	olefin	VB	O
3	3	CD	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
treated	treat	VBN	O
by	by	IN	O
sulphonyl	sulphonyl	NNP	O
chloride	chloride	NN	O
4	4	CD	O
thus	thus	RB	O
providing	provide	VBG	O
bis	bis	NN	O
-	-	HYPH	O
olefin	olefin	NN	O
5	5	CD	O
in	in	IN	O
83	83	CD	O
%	%	NN	O
yield	yield	NN	O
.	.	.	O

To	to	TO	O
obtain	obtain	VB	O
the	the	DT	O
key	key	NN	O
intermediate	intermediate	NNP	O
7	7	CD	O
,	,	,	O
the	the	DT	O
ring	ring	NN	O
closure	closure	NN	O
in	in	IN	O
compound	compound	NN	O
5	5	CD	O
was	be	VBD	O
performed	perform	VBN	O
in	in	IN	O
olefin	olefin	NNP	O
metathesis	metathesis	NN	O
conditions	condition	NNS	O
,	,	,	O
using	use	VBG	O
Ru	Ru	NNP	O
-	-	HYPH	O
catalyst	catalyst	NNP	O
6	6	CD	O
.	.	.	O

The	the	DT	O
key	key	JJ	O
intermediate	intermediate	NN	O
7	7	CD	O
was	be	VBD	O
reacted	react	VBN	O
with	with	IN	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
aryl	aryl	NNP	O
boronic	boronic	JJ	O
acids	acid	NNS	O
under	under	IN	O
Suzuki	Suzuki	NNP	O
reaction	reaction	NN	O
conditions	condition	NNS	O
and	and	CC	O
the	the	DT	O
desired	desire	VBN	O
7-aryl	7-aryl	CD	O
3H-1,2-benzoxathiepine	3h-1,2-benzoxathiepine	CD	O
2,2-dioxides	2,2-dioxides	CD	O
8â12	8â12	CD	O
were	be	VBD	O
isolated	isolate	VBN	O
in	in	IN	O
acceptable	acceptable	JJ	O
yields	yield	NNS	O
44â66	44â66	CD	O
%	%	NN	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
for	for	IN	O
the	the	DT	O
preparation	preparation	NN	O
of	of	IN	O
derivatives	derivative	NNS	O
8â12	8â12	CD	O
:	:	:	O
ICl	ICl	NNS	O
,	,	,	O
AcOH	AcOH	NNP	O
,	,	,	O
40âÂ	40ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
24âh	24âh	CD	O
,	,	,	O
84	84	CD	O
%	%	NN	O
;	;	:	O
KOtBu	KOtBu	NNP	O
,	,	,	O
CH3P3Br	CH3P3Br	NNP	O
,	,	,	O
THF	THF	NNP	O
,	,	,	O
RT	RT	NNP	O
,	,	,	O
18âh	18âh	CD	O
,	,	,	O
83	83	CD	O
%	%	NN	O
;	;	:	O
NEt3	NEt3	NNP	O
,	,	,	O
CH2Cl2	CH2Cl2	NNP	O
,	,	,	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
to	to	IN	O
RT	RT	NNP	O
,	,	,	O
4âh	4âh	CD	O
,	,	,	O
83	83	CD	O
%	%	NN	O
;	;	,	O
toluene	toluene	JJ	O
,	,	,	O
70âÂ	70âÂ	NNP	O
°	°	,	O
C	C	NNP	O
,	,	,	O
4âh	4âh	CD	O
,	,	,	O
89	89	CD	O
%	%	NN	O
;	;	:	O
Ar	Ar	NNP	O
-	-	HYPH	O
B2	B2	NNP	O
,	,	,	O
Pd4	Pd4	NNP	O
,	,	,	O
K3PO4	K3PO4	NNP	O
,	,	,	O
toluene	toluene	NNP	O
/	/	SYM	O
H2O	h2o	NN	O
,	,	,	O
100âÂ	100ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
16âh	16âh	CD	O
.	.	.	O

In	in	IN	O
an	an	DT	O
attempt	attempt	NN	O
to	to	TO	O
prepare	prepare	VB	O
6-aryl	6-aryl	CD	O
3H-1,2-benzoxathiepine	3h-1,2-benzoxathiepine	CD	O
2,2-dioxides	2,2-dioxides	CD	O
,	,	,	O
the	the	DT	O
commercially	commercially	RB	O
available	available	JJ	O
bromo	bromo	NNP	O
salicylaldehyde	salicylaldehyde	NNP	O
13	13	CD	O
was	be	VBD	O
first	first	RB	O
converted	convert	VBN	O
to	to	TO	O
olefin	olefin	VB	O
14	14	CD	O
under	under	IN	O
Wittig	Wittig	NNP	O
reaction	reaction	NN	O
conditions	condition	NNS	O
,	,	,	O
followed	follow	VBN	O
by	by	IN	O
treatment	treatment	NN	O
with	with	IN	O
sulphonyl	sulphonyl	NNP	O
chloride	chloride	NN	O
4	4	CD	O
,	,	,	O
thus	thus	RB	O
providing	provide	VBG	O
bis	bis	NN	O
-	-	HYPH	O
olefin	olefin	NN	O
15	15	CD	O
for	for	IN	O
olefin	olefin	NNP	O
metathesis	metathesis	NN	O
ring	ring	NN	O
closure	closure	NN	O
reaction	reaction	NN	O
.	.	.	O

Utilisation	utilisation	NN	O
of	of	IN	O
the	the	DT	O
Ru	Ru	NNP	O
-	-	HYPH	O
catalyst	catalyst	NNP	O
6	6	CD	O
as	as	IN	O
described	describe	VBN	O
above	above	RB	O
did	do	VBD	O
not	not	RB	O
provide	provide	VB	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
the	the	DT	O
desired	desire	VBN	O
key	key	NN	O
intermediate	intermediate	JJ	O
6-bromo	6-bromo	CD	O
3H-1,2-benzoxathiepine	3h-1,2-benzoxathiepine	CD	O
2,2-dioxide	2,2-dioxide	CD	O
even	even	RB	O
at	at	IN	O
prolonged	prolonged	JJ	O
reaction	reaction	NN	O
times	time	NNS	O
.	.	.	O

By	by	IN	O
doubling	double	VBG	O
catalyst	catalyst	NN	O
6	6	CD	O
amount	amount	NN	O
10âmol%	10âmol%	CD	O
only	only	RB	O
traces	trace	NNS	O
of	of	IN	O
compound	compound	NN	O
16	16	CD	O
were	be	VBD	O
observed	observe	VBN	O
after	after	IN	O
40âh	40âh	CD	O
.	.	.	O

No	no	DT	O
product	product	NN	O
formation	formation	NN	O
was	be	VBD	O
observed	observe	VBN	O
also	also	RB	O
when	when	WRB	O
using	use	VBG	O
Schrock	Schrock	NNP	O
and	and	CC	O
SchrockâHoveyda	SchrockâHoveyda	NNP	O
Mo	Mo	NNP	O
-	-	HYPH	O
catalysts	catalyst	NNS	O
.	.	.	O

Probably	probably	RB	O
olefin	olefin	VB	O
metathesis	metathesis	NN	O
ring	ring	NN	O
closure	closure	NN	O
reaction	reaction	NN	O
did	do	VBD	O
not	not	RB	O
take	take	VB	O
place	place	NN	O
due	due	JJ	O
to	to	IN	O
sterical	sterical	JJ	O
constraints	constraint	NNS	O
due	due	IN	O
to	to	IN	O
the	the	DT	O
bulky	bulky	NN	O
Br	br	IN	O
atom	atom	NN	O
at	at	IN	O
3-positon	3-positon	CD	O
of	of	IN	O
bis	bis	JJ	O
-	-	HYPH	O
olefin	olefin	NN	O
15	15	CD	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
KOtBu	KOtBu	NNP	O
,	,	,	O
CH3P3Br	CH3P3Br	NNP	O
,	,	,	O
THF	THF	NNP	O
,	,	,	O
RT	RT	NNP	O
,	,	,	O
18âh	18âh	CD	O
,	,	,	O
82	82	CD	O
%	%	NN	O
;	;	:	O
4	4	CD	O
,	,	,	O
NEt3	NEt3	NNP	O
,	,	,	O
CH2Cl2	CH2Cl2	NNP	O
,	,	,	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
to	to	IN	O
RT	RT	NNP	O
,	,	,	O
4âh	4âh	CD	O
,	,	,	O
66	66	CD	O
%	%	NN	O
;	;	,	O
a	a	LS	O
6	6	CD	O
5âmol%	5âmol%	CD	O
and	and	CC	O
10âmol%	10âmol%	CD	O
,	,	,	O
toluene	toluene	JJ	O
,	,	,	O
70âÂ	70âÂ	NNP	O
°	°	,	O
C	C	NNP	O
,	,	,	O
40âh	40âh	CD	O
,	,	,	O
0	0	CD	O
%	%	NN	O
;	;	,	O
b	b	LS	O
Schrock	Schrock	NNP	O
catalyst	catalyst	NN	O
10âmol%	10âmol%	CD	O
,	,	,	O
toluene	toluene	JJ	O
,	,	,	O
70âÂ	70âÂ	NNP	O
°	°	,	O
C	C	NNP	O
,	,	,	O
16âh	16âh	CD	O
,	,	,	O
0	0	CD	O
%	%	NN	O
;	;	:	O
c	c	LS	O
SchrockâHoveyda	SchrockâHoveyda	NNP	O
10âmol%	10âmol%	CD	O
,	,	,	O
toluene	toluene	JJ	O
,	,	,	O
70âÂ	70âÂ	NNP	O
°	°	,	O
C	C	NNP	O
,	,	,	O
16âh	16âh	CD	O
,	,	,	O
0%;The	0%;the	CD	O
synthesis	synthesis	NN	O
of	of	IN	O
8-bromo	8-bromo	CD	O
intermediate	intermediate	JJ	O
20	20	CD	O
was	be	VBD	O
started	start	VBN	O
from	from	IN	O
commercially	commercially	RB	O
available	available	JJ	O
aldehyde	aldehyde	NNP	O
17	17	CD	O
,	,	,	O
when	when	WRB	O
under	under	IN	O
Wittig	wittig	JJ	O
reaction	reaction	NN	O
conditions	condition	NNS	O
olefin	olefin	VBP	O
18	18	CD	O
was	be	VBD	O
obtained	obtain	VBN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
thereafter	thereafter	RB	O
treated	treat	VBN	O
with	with	IN	O
sulphonyl	sulphonyl	NN	O
chloride	chloride	NN	O
4	4	CD	O
and	and	CC	O
provided	provide	VBN	O
the	the	DT	O
bis	bis	JJ	O
-	-	HYPH	O
olefin	olefin	NN	O
19	19	CD	O
in	in	IN	O
good	good	JJ	O
yield	yield	NN	O
.	.	.	O

Ru	Ru	NNP	O
-	-	HYPH	O
catalysed	catalysed	JJ	O
olefin	olefin	NNP	O
metathesis	metathesis	NN	O
afforded	afford	VBD	O
the	the	DT	O
key	key	JJ	O
intermediate	intermediate	JJ	O
20	20	CD	O
which	which	WDT	O
in	in	IN	O
turn	turn	NN	O
,	,	,	O
by	by	IN	O
reaction	reaction	NN	O
with	with	IN	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
aryl	aryl	NNP	O
boronic	boronic	JJ	O
acids	acid	NNS	O
under	under	IN	O
Suzuki	Suzuki	NNP	O
reaction	reaction	NN	O
condition	condition	NN	O
,	,	,	O
provided	provide	VBD	O
the	the	DT	O
desired	desire	VBN	O
compounds	compound	NNS	O
21â25	21â25	CD	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
KOtBu	KOtBu	NNP	O
,	,	,	O
CH3P3Br	CH3P3Br	NNP	O
,	,	,	O
THF	THF	NNP	O
,	,	,	O
RT	RT	NNP	O
,	,	,	O
18âh	18âh	CD	O
,	,	,	O
76	76	CD	O
%	%	NN	O
;	;	:	O
4	4	CD	O
,	,	,	O
NEt3	NEt3	NNP	O
,	,	,	O
CH2Cl2	CH2Cl2	NNP	O
,	,	,	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
to	to	IN	O
RT	RT	NNP	O
,	,	,	O
4âh	4âh	CD	O
,	,	,	O
54	54	CD	O
%	%	NN	O
;	;	:	O
6	6	CD	O
,	,	,	O
toluene	toluene	JJ	O
,	,	,	O
70âÂ	70âÂ	NNP	O
°	°	,	O
C	C	NNP	O
,	,	,	O
4âh	4âh	CD	O
,	,	,	O
90	90	CD	O
%	%	NN	O
;	;	:	O
Ar	Ar	NNP	O
-	-	HYPH	O
B2	B2	NNP	O
,	,	,	O
Pd4	Pd4	NNP	O
,	,	,	O
K3PO4	K3PO4	NNP	O
,	,	,	O
toluene	toluene	NNP	O
/	/	SYM	O
H2O	h2o	NN	O
,	,	,	O
100âÂ	100ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
16âh	16âh	CD	O
.	.	.	O

The	the	DT	O
same	same	JJ	O
strategy	strategy	NN	O
was	be	VBD	O
successfully	successfully	RB	O
utilised	utilise	VBN	O
for	for	IN	O
the	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
9-aryl	9-aryl	CD	O
3H-1,2-benzoxathiepine	3h-1,2-benzoxathiepine	CD	O
2,2-dioxides	2,2-dioxides	CD	O
starting	start	VBG	O
by	by	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
aldehyde	aldehyde	NNP	O
26	26	CD	O
with	with	IN	O
methyltriphenylphosphonium	methyltriphenylphosphonium	NN	O
bromide	bromide	NN	O
under	under	IN	O
Wittig	wittig	JJ	O
reaction	reaction	NN	O
conditions	condition	NNS	O
.	.	.	O

The	the	DT	O
obtained	obtain	VBN	O
phenol	phenol	NNP	O
27	27	CD	O
was	be	VBD	O
reacted	react	VBN	O
with	with	IN	O
sulphonyl	sulphonyl	NN	O
chloride	chloride	NN	O
4	4	CD	O
and	and	CC	O
ring	re	VBG	O
closure	closure	NN	O
of	of	IN	O
isolated	isolated	JJ	O
28	28	CD	O
was	be	VBD	O
successfully	successfully	RB	O
performed	perform	VBN	O
in	in	IN	O
Ru	Ru	NNP	O
-	-	HYPH	O
catalysed	catalysed	JJ	O
olefin	olefin	NNP	O
metathesis	metathesis	NN	O
conditions	condition	NNS	O
,	,	,	O
providing	provide	VBG	O
bromide	bromide	NN	O
29	29	CD	O
.	.	.	O

Further	further	JJ	O
reaction	reaction	NN	O
of	of	IN	O
compound	compound	NN	O
9	9	CD	O
with	with	IN	O
aryl	aryl	NNP	O
boronic	boronic	JJ	O
acids	acid	NNS	O
provided	provide	VBD	O
the	the	DT	O
desired	desire	VBN	O
derivatives	derivative	NNS	O
30â34	30â34	ADD	O
in	in	IN	O
moderate	moderate	JJ	O
yields	yield	NNS	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
KOtBu	KOtBu	NNP	O
,	,	,	O
CH3P3Br	CH3P3Br	NNP	O
,	,	,	O
THF	THF	NNP	O
,	,	,	O
RT	RT	NNP	O
,	,	,	O
18âh	18âh	CD	O
,	,	,	O
80	80	CD	O
%	%	NN	O
;	;	:	O
4	4	CD	O
,	,	,	O
NEt3	NEt3	NNP	O
,	,	,	O
CH2Cl2	CH2Cl2	NNP	O
,	,	,	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
to	to	IN	O
RT	RT	NNP	O
,	,	,	O
4âh	4âh	CD	O
,	,	,	O
86	86	CD	O
%	%	NN	O
;	;	:	O
6	6	CD	O
,	,	,	O
toluene	toluene	JJ	O
,	,	,	O
70âÂ	70âÂ	NNP	O
°	°	,	O
C	C	NNP	O
,	,	,	O
4âh	4âh	CD	O
,	,	,	O
78	78	CD	O
%	%	NN	O
;	;	:	O
Ar	Ar	NNP	O
-	-	HYPH	O
B2	B2	NNP	O
,	,	,	O
Pd4	Pd4	NNP	O
,	,	,	O
K3PO4	K3PO4	NNP	O
,	,	,	O
toluene	toluene	NNP	O
/	/	SYM	O
H2O	h2o	NN	O
,	,	,	O
100âÂ	100ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
16âh	16âh	CD	O
.	.	.	O

The	the	DT	O
obtained	obtain	VBN	O
homosulfocoumarins	homosulfocoumarin	NNS	O
7â34	7â34	CD	O
were	be	VBD	O
investigated	investigate	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
CA	CA	NNP	O
inhibitory	inhibitory	NN	O
properties	property	NNS	O
by	by	IN	O
using	use	VBG	O
a	a	DT	O
stopped	stop	VBN	O
-	-	HYPH	O
flow	flow	NN	O
CO2	CO2	NNP	O
hydrase	hydrase	NN	O
assay	assay	NN	B
and	and	CC	O
four	four	CD	O
human	human	JJ	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
known	know	VBN	O
to	to	TO	O
be	be	VB	O
drug	drug	NN	O
targets	target	NNS	B
.	.	.	O

Inhibition	inhibition	NN	O
data	datum	NNS	O
of	of	IN	O
human	human	JJ	O
CA	CA	NNP	O
isoforms	isoform	VBZ	O
CA	CA	NNP	O
I	I	NNP	O
,	,	,	O
II	II	NNP	O
,	,	,	O
IX	IX	NNP	O
and	and	CC	O
XII	XII	NNP	O
with	with	IN	O
3H-1,2-benzoxathiepines	3h-1,2-benzoxathiepine	NNS	O
2,2-dioxide	2,2-dioxide	CD	O
7â34	7â34	CD	O
using	use	VBG	O
AAZ	AAZ	NNP	O
as	as	IN	O
a	a	DT	O
standard	standard	JJ	O
drug	drug	NN	O
.	.	.	O

Mean	mean	VB	O
from	from	IN	O
three	three	CD	O
different	different	JJ	O
assays	assay	NNS	O
,	,	,	O
by	by	IN	O
a	a	DT	O
stopped	stop	VBN	O
flow	flow	NN	O
technique	technique	NN	O
errors	error	NNS	O
were	be	VBD	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
Â±	Â±	NNP	O
5â10	5â10	CD	O
%	%	NN	O
of	of	IN	O
the	the	DT	O
reported	report	VBN	O
values	value	NNS	O
.	.	.	O

The	the	DT	O
following	follow	VBG	O
structure	structure	NN	O
-	-	HYPH	O
activity	activity	NN	O
relationship	relationship	NN	O
can	can	MD	O
be	be	VB	O
observed	observe	VBN	O
from	from	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
data	datum	NNS	O
of	of	IN	O
Table	table	NN	O
1.as	1.a	VBD	O
the	the	DT	O
previously	previously	RB	O
reported	report	VBN	O
homosulfocoumarins	homosulfocoumarin	NNS	B
and	and	CC	O
similar	similar	JJ	O
to	to	IN	O
sulfocoumarins	sulfocoumarin	NNS	B
,	,	,	O
also	also	RB	O
the	the	DT	O
derivatives	derivative	NNS	O
reported	report	VBN	O
here	here	RB	O
did	do	VBD	O
not	not	RB	O
significantly	significantly	RB	O
inhibit	inhibit	VB	O
the	the	DT	O
cytosolic	cytosolic	JJ	O
isoforms	isoform	NNS	O
hCA	hCA	NNP	O
I	-PRON-	PRP	O
and	and	CC	O
II	II	NNP	O
,	,	,	O
unlike	unlike	IN	O
the	the	DT	O
sulphonamide	sulphonamide	JJ	O
acetazolamide	acetazolamide	NN	O
,	,	,	O
which	which	WDT	O
has	have	VBZ	O
a	a	DT	O
very	very	RB	O
good	good	JJ	O
affinity	affinity	NN	O
for	for	IN	O
hCA	hCA	NNP	O
II	II	NNP	O
and	and	CC	O
a	a	DT	O
micromolar	micromolar	JJ	O
one	one	NN	O
for	for	IN	O
hCA	hCA	NNP	O
I	-PRON-	PRP	O
.the	.the	.	O
transmembrane	transmembrane	NNP	O
,	,	,	O
tumour	tumour	NN	O
-	-	HYPH	O
associated	associate	VBN	O
isoforms	isoform	NNS	O
hCA	hCA	NNP	O
IX	IX	NNP	O
and	and	CC	O
XII	XII	NNP	O
were	be	VBD	O
effectively	effectively	RB	O
inhibited	inhibit	VBN	O
by	by	IN	O
derivatives	derivative	NNS	O
7â29	7â29	CD	O
reported	report	VBN	O
here	here	RB	O
in	in	IN	O
the	the	DT	O
low	low	JJ	O
â	â	NNP	O
medium	medium	JJ	O
nanomolar	nanomolar	JJ	O
arneg	arneg	NN	O
and	and	CC	O
were	be	VBD	O
poorly	poorly	RB	O
inhibited	inhibit	VBN	O
,	,	,	O
in	in	IN	O
the	the	DT	O
micromolar	micromolar	JJ	O
range	range	NN	O
by	by	IN	O
the	the	DT	O
9-substituted	9-substituted	CD	O
-	-	HYPH	O
homosulfocoumarins	homosulfocoumarin	NNS	O
30â34	30â34	CD	O
KIs	ki	NNS	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
16.4â60.9âÂµM	16.4â60.9ââµm	CD	O
against	against	IN	O
hCA	hca	CD	O
IX	ix	NN	O
and	and	CC	O
>	>	XX	O
100âÂµM	100ââµm	CD	O
against	against	IN	O
hCA	hCA	NNP	O
XII	XII	NNP	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
although	although	IN	O
weak	weak	JJ	O
inhibitors	inhibitor	NNS	O
,	,	,	O
these	these	DT	O
sulfocoumarins	sulfocoumarin	NNS	O
are	be	VBP	O
anyhow	anyhow	RB	O
highly	highly	RB	O
selective	selective	JJ	O
for	for	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
hCA	hca	CD	O
IX	IX	NNP	O
,	,	,	O
whereas	whereas	IN	O
their	-PRON-	PRP$	O
activity	activity	NN	O
against	against	IN	O
hCA	hCA	NNP	O
I	I	NNP	O
,	,	,	O
II	II	NNP	O
and	and	CC	O
XII	XII	NNP	O
is	be	VBZ	O
absent	absent	JJ	O
.	.	.	O

As	as	IN	O
already	already	RB	O
anticipated	anticipate	VBN	O
above	above	RB	O
,	,	,	O
the	the	DT	O
most	most	RBS	O
important	important	JJ	O
factors	factor	NNS	O
associated	associate	VBN	O
with	with	IN	O
CA	CA	NNP	O
IX	IX	NNP	O
/	/	SYM	O
XII	XII	NNP	O
inhibitory	inhibitory	NN	O
activity	activity	NN	O
are	be	VBP	O
the	the	DT	O
position	position	NN	O
and	and	CC	O
the	the	DT	O
nature	nature	NN	O
of	of	IN	O
the	the	DT	O
moieties	moiety	NNS	O
present	present	JJ	O
on	on	IN	O
the	the	DT	O
six	six	CD	O
-	-	HYPH	O
membered	membered	JJ	O
ring	ring	NN	O
of	of	IN	O
the	the	DT	O
homosulfocoumarin	homosulfocoumarin	NN	O
.	.	.	O

Indeed	indeed	RB	O
,	,	,	O
for	for	IN	O
9-substituted	9-substituted	CD	O
derivatives	derivative	NNS	O
,	,	,	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
bulky	bulky	NN	O
,	,	,	O
substituted	substitute	VBN	O
aryls	aryls	JJ	O
as	as	IN	O
in	in	IN	O
30â34	30â34	CD	O
leads	lead	VBZ	O
to	to	IN	O
low	low	JJ	O
activity	activity	NN	O
,	,	,	O
as	as	IN	O
mentioned	mention	VBN	O
above	above	RB	O
.	.	.	O

Only	only	RB	O
the	the	DT	O
9-bromo	9-bromo	CD	O
-	-	HYPH	O
derivative	derivative	NN	O
29	29	CD	O
had	have	VBD	O
a	a	DT	O
medium	medium	JJ	O
potency	potency	NN	O
inhibitory	inhibitory	JJ	O
action	action	NN	O
against	against	IN	O
the	the	DT	O
two	two	CD	O
isoforms	isoform	NNS	O
,	,	,	O
with	with	IN	O
KIs	ki	NNS	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
754.8	754.8	CD	O
â	â	NN	O
3824ânM.	3824ânm.	CD	O
On	on	IN	O
the	the	DT	O
contrary	contrary	NN	O
,	,	,	O
the	the	DT	O
8-substituted	8-substituted	CD	O
derivatives	derivative	NNS	O
20â25	20â25	CD	O
showed	show	VBD	O
a	a	DT	O
much	much	RB	O
better	well	JJR	O
inhibitory	inhibitory	JJ	O
power	power	NN	O
against	against	IN	O
both	both	DT	O
isoforms	isoform	NNS	O
,	,	,	O
being	be	VBG	O
generally	generally	RB	O
more	more	RBR	O
potent	potent	JJ	O
than	than	IN	O
the	the	DT	O
corresponding	corresponding	JJ	O
7-substituted	7-substituted	CD	O
derivatives	derivative	NNS	O
7â12	7â12	NNS	O
.	.	.	O

Indeed	indeed	RB	O
,	,	,	O
for	for	IN	O
the	the	DT	O
7-substituted	7-substituted	CD	O
homosulfocoumarins	homosulfocoumarin	VBZ	O
the	the	DT	O
KIs	ki	NNS	O
were	be	VBD	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
66.2	66.2	CD	O
â	â	NNP	O
620.8ânM	620.8ânm	CD	O
against	against	IN	O
hCA	hCA	NNP	O
IX	IX	NNP	O
and	and	CC	O
of	of	IN	O
455.5	455.5	CD	O
â	â	NNP	O
2934ânM	2934ânm	CD	O
against	against	IN	O
hCA	hca	CD	O
XII	XII	NNP	O
.	.	.	O

On	on	IN	O
the	the	DT	O
contrary	contrary	NN	O
,	,	,	O
for	for	IN	O
the	the	DT	O
8-	8-	NNP	O
substituted	substituted	JJ	O
homosulfocoumarins	homosulfocoumarin	NNS	O
,	,	,	O
the	the	DT	O
KIs	ki	NNS	O
were	be	VBD	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
44.0	44.0	CD	O
â	â	NNP	O
104.8ânM	104.8ânm	CD	O
against	against	IN	O
hCA	hca	CD	O
IX	IX	NNP	O
and	and	CC	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
77.9	77.9	CD	O
â	â	NN	O
473.2ânM	473.2ânm	CD	O
for	for	IN	O
hCA	hca	NN	O
XII	XII	NNP	O
.	.	.	O

The	the	DT	O
8âphenyl	8âphenyl	NNP	O
-	-	HYPH	O
substituted	substitute	VBN	O
homosulfocoumarin	homosulfocoumarin	NNP	O
24	24	CD	O
was	be	VBD	O
the	the	DT	O
most	most	RBS	O
effective	effective	JJ	O
hCA	hca	NN	O
IX	IX	NNP	O
inhibitor	inhibitor	NN	O
,	,	,	O
whereas	whereas	IN	O
the	the	DT	O
corresponding	corresponding	JJ	O
4-fluorophenyl	4-fluorophenyl	CD	O
derivative	derivative	JJ	O
23	23	CD	O
was	be	VBD	O
the	the	DT	O
best	good	JJS	O
hCA	hca	CD	O
XII	xii	NN	O
inhibitor	inhibitor	NN	O
in	in	IN	O
the	the	DT	O
new	new	JJ	O
series	series	NN	O
of	of	IN	O
compounds	compound	NNS	O
investigated	investigate	VBN	O
here	here	RB	O
but	but	CC	O
it	-PRON-	PRP	O
was	be	VBD	O
an	an	DT	O
order	order	NN	O
of	of	IN	O
magnitude	magnitude	NN	O
less	less	RBR	O
effective	effective	JJ	O
compared	compare	VBN	O
to	to	TO	O
acetazolamide	acetazolamide	VB	O
.	.	.	O

A	a	DT	O
new	new	JJ	O
series	series	NN	O
of	of	IN	O
homosulfocoumarins	homosulfocoumarin	NNS	O
possessing	possess	VBG	O
various	various	JJ	O
moieties	moiety	NNS	O
in	in	IN	O
the	the	DT	O
7	7	CD	O
,	,	,	O
8	8	CD	O
or	or	CC	O
9	9	CD	O
position	position	NN	O
of	of	IN	O
the	the	DT	O
heterocylic	heterocylic	JJ	O
ring	ring	NN	O
were	be	VBD	O
prepared	prepare	VBN	O
by	by	IN	O
original	original	JJ	O
procedures	procedure	NNS	O
and	and	CC	O
investigated	investigate	VBN	O
for	for	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
four	four	CD	O
physiologically	physiologically	RB	O
relevant	relevant	JJ	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
,	,	,	O
hCA	hCA	NNP	O
I	-PRON-	PRP	O
,	,	,	O
II	II	NNP	O
,	,	,	O
IX	IX	NNP	O
and	and	CC	O
XII	XII	NNP	O
.	.	.	O

The	the	DT	O
8-substituted	8-substituted	CD	O
homosulfocoumarins	homosulfocoumarin	NNS	O
were	be	VBD	O
the	the	DT	O
most	most	RBS	O
effective	effective	JJ	O
hCA	hca	NN	O
IX	IX	NNP	O
/	/	SYM	O
XII	XII	NNP	O
inhibitors	inhibitor	NNS	O
followed	follow	VBN	O
by	by	IN	O
the	the	DT	O
7-substituted	7-substituted	CD	O
derivatives	derivative	NNS	O
,	,	,	O
whereas	whereas	IN	O
the	the	DT	O
substitution	substitution	NN	O
pattern	pattern	NN	O
in	in	IN	O
position	position	NN	O
9	9	CD	O
led	lead	VBD	O
to	to	IN	O
less	less	JJR	O
effective	effective	JJ	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
these	these	DT	O
transmembrane	transmembrane	NN	O
,	,	,	O
tumour	tumour	NN	O
-	-	HYPH	O
associated	associate	VBN	O
isoforms	isoform	NNS	O
.	.	.	O

The	the	DT	O
cytosolic	cytosolic	JJ	O
isoforms	isoform	VBZ	O
hCA	hca	VBP	O
I	-PRON-	PRP	O
and	and	CC	O
II	II	NNP	O
were	be	VBD	O
not	not	RB	O
inhibited	inhibit	VBN	O
by	by	IN	O
these	these	DT	O
compounds	compound	NNS	O
,	,	,	O
similar	similar	JJ	O
to	to	IN	O
the	the	DT	O
sulfocoumarins	sulfocoumarin	NNS	O
/	/	SYM	O
coumarins	coumarin	NNS	O
investigated	investigate	VBN	O
earlier	early	RBR	O
.	.	.	O

As	as	IN	O
hCA	hca	NN	O
IX	IX	NNP	O
and	and	CC	O
XII	XII	NNP	O
are	be	VBP	O
validated	validate	VBN	O
anti	anti	JJ	O
-	-	JJ	O
tumour	tumour	JJ	O
targets	target	NNS	B
,	,	,	O
with	with	IN	O
one	one	CD	O
sulphonamide	sulphonamide	NN	O
in	in	IN	O
Phase	Phase	NNP	O
Ib	Ib	NNP	O
/	/	SYM	O
II	II	NNP	O
clinical	clinical	JJ	O
trials	trial	NNS	O
,	,	,	O
finding	find	VBG	O
derivatives	derivative	NNS	O
with	with	IN	O
a	a	DT	O
better	well	JJR	O
selectivity	selectivity	NN	O
for	for	IN	O
inhibiting	inhibit	VBG	O
the	the	DT	O
tumour	tumour	NN	O
-	-	HYPH	O
associated	associate	VBN	O
isoforms	isoform	NNS	O
over	over	IN	O
the	the	DT	O
cytosolic	cytosolic	JJ	O
ones	one	NNS	O
,	,	,	O
as	as	IN	O
the	the	DT	O
homosulfocoumarins	homosulfocoumarin	NNS	O
reported	report	VBN	O
here	here	RB	O
,	,	,	O
is	be	VBZ	O
of	of	IN	O
crucial	crucial	JJ	O
importance	importance	NN	O
.	.	.	O

